Ecthyma Treatment in Children
Ecthyma in children requires oral antibiotic therapy for 7 days with an agent active against Staphylococcus aureus, specifically dicloxacillin or cephalexin as first-line treatment, or clindamycin, doxycycline, or trimethoprim-sulfamethoxazole when MRSA is suspected. 1
Treatment Algorithm
First-Line Oral Antibiotics (Methicillin-Susceptible S. aureus)
- Dicloxacillin or Cephalexin for 7 days 1
- These are the recommended agents because S. aureus isolates from ecthyma are usually methicillin-susceptible
- If cultures yield streptococci alone, oral penicillin becomes the agent of choice 1
When MRSA is Suspected or Confirmed
Switch to:
- Clindamycin
- Doxycycline (age considerations apply)
- Trimethoprim-sulfamethoxazole (TMP-SMX) 1
Key Clinical Distinctions
Ecthyma differs critically from impetigo in treatment approach. While impetigo can be treated with topical antibiotics (mupirocin or retapamulin), ecthyma always requires systemic oral therapy 1. This is because ecthyma represents a deeper infection extending into the dermis, unlike the superficial nature of impetigo.
Diagnostic Considerations
While Gram stain and culture of exudates are recommended to identify whether S. aureus and/or β-hemolytic Streptococcus is the causative organism, treatment without these studies is reasonable in typical cases 1. The strong recommendation (strong evidence, moderate quality) supports empiric treatment initiation without waiting for culture results.
Important Caveats
Duration Matters
The 7-day regimen is specifically recommended for ecthyma, distinguishing it from the shorter 5-day courses used for topical treatment of impetigo 1.
Topical Therapy is Inadequate
Do not use topical antibiotics alone for ecthyma. The IDSA guidelines explicitly state that "treatment for ecthyma should be an oral antimicrobial," making this a non-negotiable distinction from impetigo management 1.
Special Circumstances
During outbreaks of poststreptococcal glomerulonephritis, systemic antimicrobials should be used to help eliminate nephritogenic strains of Streptococcus pyogenes from the community 1.
Practical Implementation
The guideline evidence is endorsed by both the Infectious Diseases Society of America (IDSA) and the Pediatric Infectious Diseases Society (PIDS), providing strong consensus for pediatric application 1. The recommendations carry "strong" strength with "high" to "moderate" quality evidence, representing the highest tier of guideline recommendations available.
The choice between first-line agents (dicloxacillin vs. cephalexin) can be based on local availability, cost, and palatability in children, as both have equivalent efficacy against methicillin-susceptible S. aureus. When local MRSA prevalence is high or the patient has risk factors for MRSA (previous MRSA infection, recent hospitalization, contact sports participation), empiric coverage with clindamycin or TMP-SMX is warranted from the outset.